Avidity Biosciences, Inc. will present at the American Academy of Neurology Annual Meeting on their Phase 1/2 MARINA trial of AOC 1001 in adults with myotonic dystrophy type 1, and announced positive topline data from the trial demonstrating functional improvement, DMPK reduction, splicing improvements, and a favorable safety profile.